Last reviewed · How we verify
anti-arrhythmia agents — Competitive Intelligence Brief
phase 3
Anti-arrhythmia agents
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
anti-arrhythmia agents (anti-arrhythmia agents) — National Heart, Lung, and Blood Institute (NHLBI). Anti-arrhythmia agents work by regulating abnormal heart rhythms through various mechanisms, including blocking sodium channels, potassium channels, or calcium channels.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-arrhythmia agents TARGET | anti-arrhythmia agents | National Heart, Lung, and Blood Institute (NHLBI) | phase 3 | Anti-arrhythmia agents |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Anti-arrhythmia agents class)
- National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-arrhythmia agents CI watch — RSS
- anti-arrhythmia agents CI watch — Atom
- anti-arrhythmia agents CI watch — JSON
- anti-arrhythmia agents alone — RSS
- Whole Anti-arrhythmia agents class — RSS
Cite this brief
Drug Landscape (2026). anti-arrhythmia agents — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-arrhythmia-agents. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab